Src Tyrosine Kinase Inhibitors: New Perspectives on Their Immune, Antiviral, and Senotherapeutic Potential
José Rivera-Torres1, Esther San José1
1Department of Pharmacy, Biotechnology, Nutrition, Optics and Optometry, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid. Madrid, Spain.
Abstract:
Deregulated activity of the Src tyrosine kinases leads to malignant transformation. Since the FDA approval of the tyrosine kinase inhibitor, imatinib, in 2001 for the treatment of chronic myeloid leukemia (CML), the number of these inhibitors together with Src tyrosine kinase inhibitors (STKIs) has increased notably due to their beneficial effects. Dasatinib, a second-generation STKI inhibitor widely studied, proved high efficiency in CML patients resistant to imatinib. In the last decade STKIs have also been implicated and showed therapeutic potential for the treatment of diverse pathologies other than cancer. In this regard, we review the properties of STKIs, dasatinib in particular, including its immunomodulatory role. Similarly, the potential benefits, adverse effects, and safety concerns of these inhibitors regarding viral infections are considered. Moreover, since life expectancy has increased in the last decades accompanied by age-related morbidity, the reduction of undesirable effects associated to aging has become a powerful therapeutic target. Here, we comment on the ability of STKIs to alleviate age-associated physical dysfunction and their potential impact in the clinic.
Insights
Src tyrosine kinase inhibitors (STKIs), like dasatinib, are effective cancer treatments. Emerging research highlights their potential in treating other diseases and age-related conditions.
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Background:
- Src tyrosine kinases are crucial in cell signaling and implicated in cancer development.
- Tyrosine kinase inhibitors (TKIs), including Src tyrosine kinase inhibitors (STKIs), have advanced cancer therapy since imatinib's approval.
- Dasatinib, a potent STKI, shows efficacy in imatinib-resistant chronic myeloid leukemia (CML).
Purpose of the Study:
- To review the properties and therapeutic potential of STKIs, focusing on dasatinib.
- To explore the immunomodulatory roles of STKIs.
- To assess the safety and adverse effects of STKIs concerning viral infections and aging-related conditions.
Main Methods:
- Literature review of studies on STKIs, particularly dasatinib.
- Analysis of dasatinib's efficacy in various pathologies beyond cancer.
- Evaluation of STKIs' impact on age-associated dysfunction.
Main Results:
- STKIs demonstrate therapeutic potential in diverse diseases, not limited to cancer.
- Dasatinib exhibits immunomodulatory effects.
- STKIs may offer benefits in mitigating age-related physical decline.
Conclusions:
- STKIs, exemplified by dasatinib, possess broader therapeutic applications than initially recognized.
- Further investigation into STKIs' immunomodulatory and anti-aging properties is warranted.
- STKIs hold promise for novel clinical applications in managing chronic diseases and aging.
More Related Videos
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:26Receptor Tyrosine Kinases
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...